| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Capecitabine dosing is not yet optimized for breast cancer
|
Hudis, C.
|
|
|
21 |
11 |
p. 2291
|
article
|
| 2 |
Concomitant chemoradiation versus radical radiotherapy in advanced squamous cell carcinoma of oropharynx and nasopharynx using weekly cisplatin: a phase II randomized trial
|
Sharma, A.
|
|
|
21 |
11 |
p. 2272-2277
|
article
|
| 3 |
Distinguishing myelodysplastic syndromes (MDS) from idiopathic cytopenia of undetermined significance (ICUS): HUMARA unravels clonality in a subgroup of patients
|
Schroeder, T.
|
|
|
21 |
11 |
p. 2267-2271
|
article
|
| 4 |
Docetaxel-based combination therapy for castration-resistant prostate cancer
|
Galsky, M.D.
|
|
|
21 |
11 |
p. 2135-2144
|
article
|
| 5 |
Editorial board
|
|
|
|
21 |
11 |
p. ii-iii
|
article
|
| 6 |
Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer
|
Costa, R.B.
|
|
|
21 |
11 |
p. 2153-2160
|
article
|
| 7 |
Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study
|
Eidtmann, H.
|
|
|
21 |
11 |
p. 2188-2194
|
article
|
| 8 |
Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study
|
Ranson, M.
|
|
|
21 |
11 |
p. 2233-2239
|
article
|
| 9 |
erratum
|
|
|
|
21 |
11 |
p. 2297
|
article
|
| 10 |
High-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma
|
Glass, B.
|
|
|
21 |
11 |
p. 2255-2261
|
article
|
| 11 |
Improved survival of colon cancer due to improved treatment and detection: a nationwide population-based study in The Netherlands 1989–2006
|
van Steenbergen, L.N.
|
|
|
21 |
11 |
p. 2206-2212
|
article
|
| 12 |
in this issue
|
|
|
|
21 |
11 |
p. 2129
|
article
|
| 13 |
Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial
|
Stathopoulos, G.P.
|
|
|
21 |
11 |
p. 2227-2232
|
article
|
| 14 |
Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study
|
Rao, S.
|
|
|
21 |
11 |
p. 2213-2219
|
article
|
| 15 |
Optimising the dose of capecitabine in metastatic breast cancer: confused, clarified or confirmed?
|
Zielinski, C.
|
|
|
21 |
11 |
p. 2145-2152
|
article
|
| 16 |
Pharmacokinetics and pharmacodynamics of docetaxel with or without ketoconazole modulation in chemonaive breast cancer patients
|
Lim, Y.-W.
|
|
|
21 |
11 |
p. 2175-2182
|
article
|
| 17 |
Phase I trial of dose-escalated cisplatin with concomitant cetuximab and hyperfractionated-accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck
|
Kuhnt, T.
|
|
|
21 |
11 |
p. 2284-2289
|
article
|
| 18 |
Prediction of progressive disease using tumor markers in metastatic breast cancer patients without target lesions in first-line chemotherapy
|
Hashimoto, K.
|
|
|
21 |
11 |
p. 2195-2200
|
article
|
| 19 |
Prognostic role of platinum sensitivity in patients with brain metastases from ovarian cancer: results of a German multicenter study
|
Sehouli, J.
|
|
|
21 |
11 |
p. 2201-2205
|
article
|
| 20 |
Radiographic regression of vestibular schwannomas induced by bevacizumab treatment: sustain under continuous drug application and rebound after drug discontinuation
|
Mautner, V.-F.
|
|
|
21 |
11 |
p. 2294-2295
|
article
|
| 21 |
Reply to Capecitabine dosing is not yet optimized for breast cancer
|
Zielinski, C.
|
|
|
21 |
11 |
p. 2291-2292
|
article
|
| 22 |
Response assessment by combined PET–CT scan versus CT scan alone using RECIST in patients with locally advanced head and neck cancer treated with chemoradiotherapy
|
Passero, V.A.
|
|
|
21 |
11 |
p. 2278-2283
|
article
|
| 23 |
Serious pulmonary toxicity in patients with Hodgkin’s lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism
|
Blum, K.A.
|
|
|
21 |
11 |
p. 2246-2254
|
article
|
| 24 |
Silent hereditary hematochromatosis as a susceptibility factor of doxorubicin-induced acute cardiac failure
|
Penel, N.
|
|
|
21 |
11 |
p. 2293-2294
|
article
|
| 25 |
Surveillance CT scans are a source of anxiety and fear of recurrence in long-term lymphoma survivors
|
Thompson, C.A.
|
|
|
21 |
11 |
p. 2262-2266
|
article
|
| 26 |
Survival after organ preserving treatment for T4a laryngeal squamous cell carcinoma
|
Hamdan, J.
|
|
|
21 |
11 |
p. 2292-2293
|
article
|
| 27 |
Survival differences among women with de novo stage IV and relapsed breast cancer
|
Dawood, S.
|
|
|
21 |
11 |
p. 2169-2174
|
article
|
| 28 |
Survival of breast cancer patients with meningeal carcinomatosis
|
Gauthier, H.
|
|
|
21 |
11 |
p. 2183-2187
|
article
|
| 29 |
Symptomatic brain metastases from small-cell carcinoma of the urinary bladder: The Netherlands Cancer Institute experience and literature review
|
Bex, A.
|
|
|
21 |
11 |
p. 2240-2245
|
article
|
| 30 |
Table of Contents
|
|
|
|
21 |
11 |
p. iv-v
|
article
|
| 31 |
The need to promote independent research on drugs
|
Traversa, G.
|
|
|
21 |
11 |
p. 2295
|
article
|
| 32 |
Trastuzumab beyond progression: a challenge to translational oncology?
|
Santoro, A.
|
|
|
21 |
11 |
p. 2131-2134
|
article
|
| 33 |
Trastuzumab beyond progression: a cost-utility analysis
|
Matter-Walstra, K.W.
|
|
|
21 |
11 |
p. 2161-2168
|
article
|
| 34 |
Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24 †
|
Goodwin, R.
|
|
|
21 |
11 |
p. 2220-2226
|
article
|
Journal description